CN1243721A - 治疗白血病的誉白正血丸 - Google Patents
治疗白血病的誉白正血丸 Download PDFInfo
- Publication number
- CN1243721A CN1243721A CN 98103528 CN98103528A CN1243721A CN 1243721 A CN1243721 A CN 1243721A CN 98103528 CN98103528 CN 98103528 CN 98103528 A CN98103528 A CN 98103528A CN 1243721 A CN1243721 A CN 1243721A
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- pill
- leukemia
- leukemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006187 pill Substances 0.000 title claims abstract description 15
- 208000032839 leukemia Diseases 0.000 title abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 3
- 241000628997 Flos Species 0.000 claims description 10
- 241000411851 herbal medicine Species 0.000 claims description 7
- 241000756943 Codonopsis Species 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 5
- 241001250596 Pleione Species 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 241000893536 Epimedium Species 0.000 abstract 1
- 244000056623 Iphigenia indica Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000024207 chronic leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003003 monocyte-macrophage precursor cell Anatomy 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001161070 Calomela Species 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018275 Gingival atrophy Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010048612 Hydrothorax Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000227425 Pieris rapae crucivora Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229910052957 realgar Inorganic materials 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗白血病的药物,特别是涉及采用中草药的组合药剂治疗白血病的誉白正血丸。它含有金银花、山慈姑、淫羊霍、巴戟天、黄芪、白芍、桃仁、桅子、大黄、党参、生地、红花等中草药按一定配比,经干燥或烘干粉碎研成细末,过筛混均成散剂,或蜜丸或制成水剂型颗粒丸。治疗白血病的誉白正血丸使用方便,治疗白血病具有独特疗效。
Description
本发明涉及一种治疗白血病的药物，特别是涉及一种以中草药为原料制备治疗白血病的誉白正血丸。
大家知道，白血病是造血系统的恶性疾病，俗称血癌，是死亡率最高的血液恶性肿瘤，其特征是：白细胞及其幼稚胞在全身各脏器官广泛无限制的异常增生，使外周血象及骨髓象中细胞发生数量和质量的变化，临床上表现为出现贫血、发热出血、肝、脾、淋巴结肿大、脏器受浸润等一系列征象，分为急性粒单细胞白血病、急性淋巴细胞性白血病，急性早幼粒白血病、急性单核细胞白血病，总称急粒、慢性白血病，有慢淋、慢粒、慢单等。
当前西医对白血病的治疗都有采用缓解化疗法，化疗药物有强的松、长春花硷、长春新硷、柔毛霉素(又名正定霉素)，左旋门冬酰安酶等十来种，这些药物对白血病具有减轻病情发展、抑制血液中癌细胞增殖，杀死癌细胞。缓解率：对儿童患者达57-91％，对成人患者达41-53％，但是服用药副作用明显，化疗药物在杀死癌细胞同时，也杀死血液、骨髓中的正常细胞，造成两败具伤。另外服药后病人有心动过速，心律不齐、食欲减退、恶心、呕吐反应，对肝、脾功能有损伤作用，使患者身体免疫力下降，抗病能力差，治愈率低。
西医可以通过外科手术，进行骨髓移植办法来治疗白血病，但手术费高昂，具有相同骨髓象的人才能移植，对于一位普通白血病人，能找到能提供移植骨髓的人极少，给实施手术治疗造成很大困难。
中医认为白血病的病因是营血亏耗所出现的症状。由于血亏少气，气血运行失畅，痰阻血瘀，随之而生，临床上分为急劳(急性白血病)，虚劳(慢性白血病)两类。急劳症状表现为壮热，烦躁、口渴多汗，面赤头痛、口舌生疮或见吐血，衄血、便血、尿血、斑疹诸症，舌质红，舌苔黄脉大；而虚劳症状则表现为，发热盗汗，口苦口干，渴喜饮水，或见牙宣、鼻衄，皮肤瘀点瘀斑，舌质红，苔黄、脉象细数。当前中医对白血病治疗大多采用清热解毒化瘀散结，活血化瘀、扶正培本的有关中草药，有一定疗效。但不理想，疗效缓慢。有人用三尖杉酯类生物硷治疗急性白血病，缓解率达20.6-50％，用高三尖杉酯治疗急性非淋巴细胞白血病缓解率在19.3-60％，有人从青黛中提取的靛至红治疗慢性白血病，缓解率为59.87％，用单药提取物治疗，疗效不太理想，有轻微副作用。
CN1092988A，93103708.5，一种治疗白血病的中药，该项申请公布了治疗白血病的三个配套药方，I号方为红宝丹，II号方为补元散，III号方为生血丸。该申请可治疗各种类型白血病，总有效率达95％，治愈率缓解率为45％，有较好疗效。但用药多达约57种中草药，配方较复杂，较难配齐，有些有毒如灸水银，轻粉、红茅大戟、雄黄等；有的市场上较难买到，如牛骨髓油等。
CN1106269A，CN1106269A，对应申请号为93120413.5，93120412.7，一种治疗白血病的中草药组合物及其逆转细胞汤和再生细胞汤的制备方法。二项申请公开了治疗白血病的二个水煎药方剂，以及单味药予炮制，药引子，加热煎者的制备方法，这二个配套使用方剂在长达8年中对180例白血病患者进行服药后观察、分析、随访，痊愈率25％，基本痊愈(部分缓解)率68.9％，无效率6.1％，总有效率达93.9％，取得较好疗效。但从申请文件来看，这二项申请好象实用性有些问题，就是说，它能否实现工业化的生产，值得怀疑。因为童尿、白马溺(白马尿)、鹿血、能否获得工业化生产需要的供应不得而知。
本发明的目的是采用一般易得的中草药，进行配伍研究，制出治疗白血病的誉白正血丸，本发明的技术方案是：按重量配比，含有下述原料的中草药制成的药剂：金银花 5-15，黄芪 10-30，大黄 10-15，山慈姑 10-20，白芍 10-30，淫羊藿10-20，党参 10-20，桃仁 10-15，巴戟天 10-20，生地 10-20，栀子 10-20，红花 10-15。
所说的药制可为散剂或丸剂。
按一定配比，先将金银花、山慈姑、淫羊藿、巴戟天、黄芪、白药、桃仁、栀子、大黄、党参、生地、红花净土去杂干燥或烘干，粉碎研成细末，过60目筛，混合拌均成散剂或蜜丸或制成水剂型颗粒丸。
本发明的实施具有积极明显效果。
1、对白血病治疗效果较好，特别是对急性白血病有独特疗效。
2、服药方便，减少病人许多麻烦。
3、易进行工业化生产，易推广应用。
实施例：重量配比按千克金银花15，白芍15，桃仁10，巴戟天15，党参10，栀子10，山慈姑10，红花10，大黄15，淫羊藿10，黄芪15，生地15按重量比例称出各种中草药的重量，净土去杂，干燥或烘干后粉碎研成细末，过60目筛，混均成散剂，或蜜丸，或制成水剂型的颗粒丸。病例举例：
张××，河南省虞城县防疫站职工，1997年患白血病，病情十分严重，白血球58000，血小板40000，血色素3.5克，经骨髓穿刺检查，原始单核细胞占95％，胸腔积液，昏迷不醒，肝、脾肿大，高烧，头晕耳鸣，骨瘦如柴，饮食不下，下肢、胸背有出血点，牙龈出血，头发脱落，双目接近失明，四肢无力，腹水，周身浮肿，到医院治疗未好转。1997年8月8日服治疗白血病的誉白正血丸，一个月后到地区医院进行骨髓检查，原始单核细胞恢复正常，病情痊愈。
李××，女，32岁，河南省虞城县城关镇吴南庄，患白血病，经骨髓检查早幼粒为95％，血色素4.8克，红细胞300万，血小板3万，白细胞9万，在地区医院进行化疗求治，效果甚微，病情一天天加重，后服治疗白血病的誉白正血丸，2个月疗程，经地区医院检查，各项指标恢复正常，已治愈。
Claims (3)
1、一种治疗白血病的誉白正血丸，其特征在于：按重量配比，含有下述原料的中草药制成的药剂：金银花 5-15， 黄芪 10-30，大黄 10-15，山慈姑 10-20，白芍 10-30，淫羊藿 10-20，党参 10-20，桃仁 10-15，巴戟天 10-20，生地 10-20，栀 子 10-20，红花 10-15。
2、根据权利要求1所述的药物，其特征是：所说的药制可为散剂或丸剂。
3、根据权利要求1或者所述的药物，其特征是：按一定配比，先将金银花、山慈姑、淫羊藿、巴戟天、黄芪、白药、桃仁、栀子、大黄、党参、生地、红花净土去杂干燥或烘干，粉碎研成细末，过60目筛，混合拌均成散剂或蜜丸或制成水剂型颗粒丸。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98103528A CN1098698C (zh) | 1998-07-31 | 1998-07-31 | 治疗白血病的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98103528A CN1098698C (zh) | 1998-07-31 | 1998-07-31 | 治疗白血病的药物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1243721A true CN1243721A (zh) | 2000-02-09 |
| CN1098698C CN1098698C (zh) | 2003-01-15 |
Family
ID=5217968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98103528A Expired - Fee Related CN1098698C (zh) | 1998-07-31 | 1998-07-31 | 治疗白血病的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1098698C (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249243B (zh) * | 2008-04-08 | 2011-12-07 | 屈凤星 | 一种治疗急性白血病的中药 |
| CN104587300A (zh) * | 2015-02-04 | 2015-05-06 | 张延德 | 用于治疗急性白血病的中药组合物及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157166A (zh) * | 1996-01-25 | 1997-08-20 | 温顺明 | 血复康 |
| CN1060079C (zh) * | 1997-01-17 | 2001-01-03 | 任玉让 | 治疗白血病的中草药组合物 |
-
1998
- 1998-07-31 CN CN98103528A patent/CN1098698C/zh not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101249243B (zh) * | 2008-04-08 | 2011-12-07 | 屈凤星 | 一种治疗急性白血病的中药 |
| CN104587300A (zh) * | 2015-02-04 | 2015-05-06 | 张延德 | 用于治疗急性白血病的中药组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1098698C (zh) | 2003-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101961464B (zh) | 一种治疗黄疸的中药组合物及其制备方法 | |
| CN101670071A (zh) | 治疗癌症的中药制剂及其制备方法 | |
| CN102210847A (zh) | 治疗痛经的药物组合物胶囊的制备方法及其应用 | |
| CN103041317B (zh) | 一种治疗肿瘤的中药组合物及其制备方法 | |
| CN100460008C (zh) | 治疗癌症的中药组合物 | |
| CN111375010A (zh) | 一种具有扶正固本，补肝益肾，增强免疫功效的中药组合物 | |
| CN105535471A (zh) | 一种用于治疗神经衰弱的丸剂药物及其制备方法 | |
| CN102552517A (zh) | 妇科无糖型妇康宝颗粒剂及其制备方法 | |
| CN101897821B (zh) | 一种活血通络止痛的颗粒剂及其制备和检测方法 | |
| CN101085251A (zh) | 治疗肾病综合征的一种中药制剂 | |
| CN1098698C (zh) | 治疗白血病的药物及其制备方法 | |
| CN101954022B (zh) | 一种用于治疗肺癌的中药组合物 | |
| CN1326551C (zh) | 一种用于辅助治疗恶性肿瘤的制剂及其制备方法 | |
| CN104042981A (zh) | 一种治疗产后便秘的药剂及制备方法 | |
| CN102885953A (zh) | 一种用于补肾健脾的中药制剂及其制备工艺 | |
| CN1318058C (zh) | 一种治疗乳腺增生疾病的浓缩丸制备方法 | |
| CN101574458A (zh) | 一种治疗肾虚阳萎的中药制剂 | |
| CN1106850C (zh) | 补肾强身胶囊 | |
| CN101850101B (zh) | 一种治疗漏下的中药组合物及其制备方法 | |
| CN102940773A (zh) | 抑制肝癌转移的中药制剂及其制备方法 | |
| CN103736008B (zh) | 治疗乳腺癌并发健侧良性包块的药物组合物及其制备方法 | |
| CN100396309C (zh) | 一种增强人体抵抗力和免疫力的药物 | |
| CN104491585A (zh) | 风湿性关节炎祛风胜湿膏及制备方法 | |
| CN103735635A (zh) | 一种治疗癌症和白血病的药物组合物 | |
| CN101032613B (zh) | 一种治疗肝囊肿的中药制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |